Arthritis Research & Therapy最新文献

{"title":"Reversing detrimental effects of OA-related terminal maturation in high-throughput in vitro and biomimetic ex vivo human models","authors":"I. Boone,N. Korthagen,K. Sivasubramaniyan,R. Mahdad,R. G. H. H. Nelissen,B. Coornaert,M. A Tessari,I. Meulenbelt","doi":"10.1186/s13075-026-03903-w","DOIUrl":"https://doi.org/10.1186/s13075-026-03903-w","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"12 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149049135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Induction of a non-inflammatory macrophage phenotype M2 (CD206⁺MerTK⁺) by prednisolone and CTLA4-Ig (abatacept) combined treatment in cultured monocyte-derived macrophages from early diagnosed rheumatoid arthritis patients","authors":"Stefano Soldano,Paola Montagna,Rosanna Campitiello,Elvis Hysa,Carmen Pizzorni,Sabrina Paolino,Alberto Sulli,Vanessa Smith,Emanuele Gotelli,Maurizio Cutolo","doi":"10.1186/s13075-026-03897-5","DOIUrl":"https://doi.org/10.1186/s13075-026-03897-5","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"1 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149020611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic and clinical features of systemic sclerosis patients with anti-U1RNP antibodies: an European Scleroderma Trials and Research (EUSTAR) analysis","authors":"Wanlong Wu,Madeleine Venables,Eric Hachulla,Liala Moschetti,Marco Matucci-Cerinic,Francesca Cozzi,Yannick Allanore,Patricia E. Carreira,Andra Balanescu,Ivan Castellví,Alberto Cauli,Christopher P. Denton,Michele Iudici,Vincent Sobanski,Ulf Mueller-Ladner,Elena Rezus,Simona Truglia,Gabriela Riemekasten,Bojana Stamenkovic,Elisabetta Zanatta,Francesco Del Galdo,Masataka Kuwana,Marie-Elise Truchetet,Shuang Ye,Suzana Jordan,Rucsandra Dobrota,Oliver Distler,the EUSTAR co-authors","doi":"10.1186/s13075-026-03902-x","DOIUrl":"https://doi.org/10.1186/s13075-026-03902-x","url":null,"abstract":"Abstract Objective To investigate the demographic and clinical features of systemic sclerosis (SSc) patients with anti-U1RNP antibodies using the European Scleroderma Trials and Research (EUSTAR) database, a phenotype less well-defined in SSc than other more commonly associated antibodies. Methods SSc patients fulfilling classification criteria with available data on anti-U1RNP antibodies were analyzed. Clinical characteristics were collected when the status of anti-U1RNP antibodies was first recorded and patients positive/negative for anti-U1RNP antibodies were compared by univariable analysis. Associations between anti-U1RNP status and organ involvement were assessed by multivariable logistic regression. Multiple imputation used for missing data. Results A total of 8391 patients were eligible for this analysis, among which 408 (4.9%) were positive for anti-U1RNP antibodies. By multivariable analysis, anti-U1RNP antibodies were confirmed independently associated with younger age at disease onset (OR 0.96, 95% CI 0.95 to 0.97), synovitis (OR 1.82, 95% CI 1.20 to 2.77), pulmonary hypertension on echocardiography (OR 2.13, 95% CI 1.41 to 3.20), proteinuria (OR 2.25, 95% CI 1.29 to 3.93), lower mRSS (OR 0.95, 95% CI 0.93 to 0.98) and elevated ESR (OR 1.48, 95% CI 1.03 to 2.12). There was a negative association with White patients (OR 0.25, 95% CI 0.17 to 0.37). Conclusion This is the largest cohort of SSc patients positive for anti-U1RNP antibodies reported. It defines a distinct clinical phenotype, with predilection for non-white race, younger disease onset, more inflammatory and musculoskeletal, cardiopulmonary or renal involvement. The detection of anti-U1RNP antibodies in SSc patients might be helpful for risk stratification in clinical practice.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"6 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149020610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib therapy improves disease activity and is associated with the restoration of CD4+ regulatory T cell homeostasis in active Takayasu arteritis: a two-year prospective open-label cohort study","authors":"Jing Luo,Jing Zhang,Bomiao Ju,Yanhua Wang,Nan Hu,Qian Li,Qianyun Xu,Zhiming Hao,Yongwei Huo,Xiaofeng Yang,Yun Zhang,Xiaohong Lv,Lan He","doi":"10.1186/s13075-026-03901-y","DOIUrl":"https://doi.org/10.1186/s13075-026-03901-y","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"26 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149020629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase 4, open-label efficacy and safety study of methotrexate and monthly pegloticase co-administration in patients with uncontrolled gout","authors":"Orrin M. Troum,John K. Botson,Fang Fang,Afroz S. Mohammad,Supra Verma,Brian LaMoreaux","doi":"10.1186/s13075-026-03884-w","DOIUrl":"https://doi.org/10.1186/s13075-026-03884-w","url":null,"abstract":"Abstract Background Pegloticase is an infused pegylated uricase enzyme indicated for the treatment of uncontrolled gout in adults who did not respond to or cannot tolerate oral urate-lowering therapies; pegloticase is administered as 8-mg infusions every 2 weeks (Q2W). However, frequent infusions can create a logistical burden for patients. The phase 4, FORWARD open-label trial (NCT04762498) assessed the efficacy and safety of less frequent and higher dose pegloticase infusions in patients with uncontrolled gout. Methods Adults with uncontrolled gout received either 16-mg or 30-mg pegloticase infusions, co-administered with methotrexate, every 4 weeks (Q4W) through the 24-week trial, with an optional extension through Week 48. The primary endpoints were the percentage of responders during Month 6 (those with serum uric acid [sUA] < 6 mg/dL for ≥ 80% of the time during Month 6) and the time to the first sUA level ≥ 6 mg/dL after achieving sUA < 6 mg/dL through Week 24. Other key endpoints included pharmacokinetic parameters, adverse events (AEs), and antidrug antibody profiles. Results The percentages of Month 6 responders in the 16-mg cohort ( n  = 25) and 30-mg cohort ( n  = 26) were 68.0% and 73.1%, respectively. The median time to the first sUA level ≥ 6 mg/dL after achieving sUA < 6 mg/dL was 50.5 days in the 16-mg cohort and 22.5 days in the 30-mg cohort for those with events, but the median time to this endpoint among all patients was not estimable using Kaplan–Meier due to the low number of events. Safety results were similar between cohorts. Gout flares occurred in 72.0% and 77.0% of patients in the 16- and 30-mg cohorts, respectively. Serious treatment-emergent AEs occurred in three patients in the 16-mg cohort. Immunogenicity findings were similar to those established with 8-mg pegloticase Q2W with methotrexate. Conclusions The efficacy and safety findings from this study of monthly 16- and 30-mg pegloticase dosing are consistent with results from standard biweekly 8-mg dosing, indicating that a less frequent and higher dosed pegloticase treatment schedule co-administered with methotrexate is feasible for patients with uncontrolled gout. Trial registration ClinicalTrials.gov NCT04762498 (registered on 17 February 2021).","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"2 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149020628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early development of LRX712, preclinical chondroanabolic findings and results from a randomized first-in-human study","authors":"Anouk C. Meijs,Josephina P.M. Vrouwe,Franziska Saxer,Ina Kramer,Angelika Meyer,Jimmy Elliott,Christian Kolter,Serge Summermatter,Gerard Bruin,Azeddine Elhajouji,Frederik E. Stuurman,Jacobus Burggraaf,Andreas Fisch,Bernd Riebesehl,Nicole Gerwin,Sabine Guth-Gundel,Kristen Johnson,Pia Kuss,Stephan Utzinger,David Sanchez-Ramos,Laura Coleman,Celeste Scotti,Karin Meiser,Michaela Kneissel,Ronenn Roubenoff,Naomi B. Klarenbeek,Matthias Schieker","doi":"10.1186/s13075-026-03900-z","DOIUrl":"https://doi.org/10.1186/s13075-026-03900-z","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"64 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149020630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of lung ultrasound for the detection of interstitial lung disease in rheumatoid arthritis: a systematic review and meta-analysis","authors":"Davide Mohammad Reza Beigi,Greta Pellegrino,Marco Davide Dal Fabbro,Marius Cadar,Francesca Romana Di Ciommo,Jacopo Landro,Nicholas Landini,Simona Truglia,Fabrizio Conti,Georgios Filippou,Valeria Riccieri","doi":"10.1186/s13075-026-03890-y","DOIUrl":"https://doi.org/10.1186/s13075-026-03890-y","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"104 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149020631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrovascular damage in polymyalgia rheumatica: integrated vascular phenotyping in the POLYMYACARD cohort.","authors":"Sarah Wagner, Anna-Lena Zang, Markus Scheppers, Clio Mavragani, Jisna Paul, Ioannis Parodis, Dionysis Nikolopoulos, Andreas Schwarting, Konstantinos Triantafyllias","doi":"10.1186/s13075-026-03886-8","DOIUrl":"10.1186/s13075-026-03886-8","url":null,"abstract":"<p><strong>Background: </strong>To evaluate, for the first time, a wide combination of oscillometric and sonographic markers of macrovascular damage in patients with polymyalgia rheumatica (PMR), using carotid-femoral pulse wave velocity (cfPWV) and carotid greyscale/colour Doppler ultrasound (GSUS/CDUS). Additionally, to explore associations between these markers, traditional cardiovascular (CV) risk factors, and inflammatory parameters.</p><p><strong>Methods: </strong>Aortic stiffness was assessed by cfPWV. GSUS measured carotid intima-media thickness (cIMT), plaque presence, and cumulative plaque area. CDUS assessed haemodynamic/compliance surrogates, including resistance index (RI), pulsatility index (PI) in the common (CCA), internal (ICA), and external (ECA) carotid arteries. Multivariable linear regression (MLR) and propensity score matching (PSM) adjusted for confounding.</p><p><strong>Results: </strong>cfPWV was obtained in 72 PMR patients; 26 also underwent GSUS/CDUS. Compared with controls, PMR patients had higher cfPWV (p_adj=0.012), increased RI (p_adj=0.020), and PI (p_adj=0.027) in the ECA after MLR and PSM. PSM further indicated a higher prevalence of subclinical arteriosclerosis in PMR [13/16 (81.3%) vs. 7/16 (43.8%); adjusted p = 0.028]. Plaque area was greater in patients with elevated C-reactive protein [0.41 (0.13-1.07) vs. 0.05 (0.00-0.31); p = 0.016]. cfPWV and carotid markers correlated with age (cfPWV r = 0.588, p < 0.001; cIMT r = 0.542, p = 0.004; plaques r = 0.662, p < 0.001) and mean arterial pressure (cfPWV ρ = 0.247, p = 0.038; cIMT r = 0.515, p = 0.020; plaques r = 0.596, p = 0.006).</p><p><strong>Conclusions: </strong>Patients with PMR exhibited increased aortic stiffness and elevated carotid pulsatility and resistance in the ECA compared with controls, independent of traditional CV risk factors. These non-invasive vascular markers may help identify PMR patients at increased CV risk and support integrated CV risk assessment in clinical care.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13576255/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential regulation of SOCS signalling and immunoproteasome pathways by JAK inhibitors and TNF inhibitors in rheumatoid arthritis.","authors":"Khetam Ghannam, Linh Nguyen My, Christine Behrendt, Monika Brunner-Weinzierl, Anke Lux, Jessica Bertrand, André Wille, Mandy Gläß, Stephan Heinemann-Dammann, Katrin Borucki, Eugen Feist","doi":"10.1186/s13075-026-03895-7","DOIUrl":"10.1186/s13075-026-03895-7","url":null,"abstract":"<p><strong>Background: </strong>Janus kinase (JAK) inhibitors and TNF inhibitors (TNFi) are established therapies in rheumatoid arthritis (RA), yet their differential effects on the JAK/STAT/SOCS/proteasome axis remain incompletely understood. This pilot study systematically characterised treatment-specific effects of baricitinib, tofacitinib, and TNFi upon molecular signatures in RA patients.</p><p><strong>Methods: </strong>Seventy-five patients with RA were enrolled across two prospective cohorts: an initial inception cohort treated with tofacitinib (n = 15) and a subsequent confirmatory cohort treated with baricitinib or TNFi (n = 60; baricitinib n = 29, TNFi n = 31), along with 17 and 33 healthy donors (HD)serving as controls for each cohort, respectively. mRNA expression of SOCS1, SOCS2, SOCS3, CIS1, and the immunoproteasome subunit β2i was assessed in peripheral blood mononuclear cells by real-time PCR. SOCS2 protein levels were measured by ELISA, and serum IL-6 levels were evaluated in the baricitinib/TNFi cohort.</p><p><strong>Results: </strong>Responder rates were comparable across all three treatment groups at both time points. JAK inhibition was associated with a distinct SOCS suppression signature: SOCS2 mRNA declined progressively under both baricitinib and tofacitinib but not under TNFi blockade. SOCS1 and SOCS3 mRNA normalized under baricitinib over time, while SOCS3 elevation persisted throughout the observation period under TNFi. CIS1 was selectively suppressed under baricitinib. Partial discordance between SOCS2 mRNA and protein levels suggested post-transcriptional regulation. Baseline SOCS3 expression was significantly higher in baricitinib non-responders than responders, and early SOCS3 decline at 2 weeks distinguished TNFi responders from non-responders. Proteasomal β2i mRNA was relatively upregulated under tofacitinib and TNFi but not under baricitinib.</p><p><strong>Conclusion: </strong>JAK inhibition drives a treatment-specific suppression of SOCS family members not observed under TNFi, reflecting differential remodelling of cytokine feedback networks. Baseline and early SOCS3 dynamics emerge as candidate biomarkers of treatment response. These findings may inform future efforts to personalise treatment selection in RA and warrant validation in larger, randomised cohorts.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"28 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13576232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148975272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HLA-B*27-associated arthritis across the ages – bridging the gap","authors":"Corinne Fisher,Sahar Lotfi-Emran,Robert A. Colbert","doi":"10.1186/s13075-026-03870-2","DOIUrl":"https://doi.org/10.1186/s13075-026-03870-2","url":null,"abstract":"","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"269 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149020280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}